Concit Pharma presents JM-010 at Sydney meeting

Concit Pharma will present JM-010 at the Movement Disorder Society meeting in Sydney, Australia June 16-20. The preclinical data suppporting the efficacy and safety of JM-010 as a new drug for treatment of L-DOPA induced dyskinesia will be presented on a poster. A copy of the poster can be obtained upon request ([email protected]) .

The release as fetched from its publisher. conterapharma.com ↗